bluuebunny/crossref_metadata_2025_split huggingface dataset:
Effectiveness of moisturising therapy in treating nipple trauma: a systematic review protocol
Authors: Nakamura Maya , Luo Yunjie , Ebina Yasuhiko 
Published: September 2024

IntroductionBreastfeeding is crucial in infant nutrition and bonding, recommended for at least 6 months and up to 2 years postpartum, providing health benefits for both infants and mothers. However, nipple trauma is common among lactating mothers. Moisturising therapies, such as hydrogel application, aim to promote the healing of nipple wounds. Despite various interventions proposed, comprehensive reviews evaluating the efficacy of moisturising therapies for nipple trauma are lacking. This review aims to appraise the effectiveness of moisturising therapy, particularly tailored for nipple trauma in lactating women.Methods and analysisThis systematic review protocol adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines and is registered in the International Prospective Register of Systematic Reviews. The focus will be on both randomised and non-randomised controlled trials addressing the treatment of nipple trauma in lactating women. In this context, ‘moisturising therapy’ is categorised as a non-pharmacological intervention applied directly to the nipple, excluding treatments for bacterial or fungal infections. The primary outcomes will include measures of the healing efficiency of nipple trauma and reduction in nipple pain. Searches will be conducted without date restrictions across multiple databases, including PubMed, CINAHL, the Cochrane Library, Web of Science, CiNii Research and Ichushi-Web, in addition to exploration of grey literature. Two independent reviewers will manage all stages of the review process, under the supervision of a third reviewer. Data extraction will encompass participant demographics, study methodologies, sample specifics and measured outcomes. Quality assessment will be conducted using the Joanna Briggs Institute Appraisal Checklist Tools.Ethics and disseminationEthics approval is not required for this study. The findings of this review will be disseminated through academic publications, detailed reports and presentations at relevant conferences.PROSPERO registration numberCRD42023481761.
Financial toxicity of cancer care in sub-Saharan Africa: protocol for a systematic review
Authors: Ida Akiko , Htay Zin Wai 
Published: September 2024

IntroductionIn sub-Saharan Africa (SSA), the number of cancer deaths is expected to double between 2020 and 2030; however, financial costs remain a barrier to accessing cancer treatment and care. There is an evidence gap on financial toxicity related to cancer care in SSA, both for the patient and for the family members providing care. Against this background, this review aims to analyse cancer care-related financial toxicity for the patient and family caregivers in SSA.Methods and analysisA comprehensive search of peer-reviewed articles in the English language reporting the financial burden of cancer care on patients and family caregivers in SSA will be conducted using PubMed, Scopus and Web of Science from 1 January 2000 to 13 October 2023. Two researchers will independently review the titles, abstracts and full-text articles, and any disagreements will be resolved through consensus. A risk of bias assessment will be conducted using the assessment tools from the Joanna Briggs Institute Critical Appraisal Checklist. A quantitative and narrative synthesis of included studies, including the prevalence of financial toxicity of cancer care in SSA, will be developed. The review will be reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.Ethics and disseminationEthical review is not required because this review draws on published literature. The results will be presented at leading cancer and public health conferences, published in peer-reviewed journals and disseminated via website posts and social media channels to improve access to cancer care and to facilitate evidence-based policymaking in SSA.PROSPERO registration numberCRD42023469011.
Preterm birth as a determinant of neurodevelopment and cognition in children (PRENCOG): protocol for an exposure-based cohort study in the UK
Authors: Boardman James P , Andrew Ruth , Bastin Mark E , Battersby Cheryl , Batty G David , Cábez Manuel Blesa , Cox Simon R , Hall Jill , Ingledow Lauren , Marioni Riccardo E , Modi Neena , Murphy Lee , Quigley Alan J , Reynolds Rebecca M , Richardson Hilary , Stock Sarah J , Thrippleton Michael J , Tsanas Athanasios , Whalley Heather C 
Published: September 2024

IntroductionPreterm birth (PTB) is strongly associated with encephalopathy of prematurity (EoP) and neurocognitive impairment. The biological axes linking PTB with atypical brain development are uncertain. We aim to elucidate the roles of neuroendocrine stress activation and immune dysregulation in linking PTB with EoP.Methods and analysisPRENCOG (PREterm birth as a determinant of Neurodevelopment and COGnition in children: mechanisms and causal evidence) is an exposure-based cohort study at the University of Edinburgh. Three hundred mother–infant dyads comprising 200 preterm births (gestational age, GA <32 weeks, exposed) and 100 term births (GA >37 weeks, non-exposed), will be recruited between January 2023 and December 2027. We will collect parental and infant medical, demographic, socioeconomic characteristics and biological data which include placental tissue, umbilical cord blood, maternal and infant hair, infant saliva, infant dried blood spots, faecal material, and structural and diffusion MRI. Infant biosamples will be collected between birth and 44 weeks GA.EoP will be characterised by MRI using morphometric similarity networks (MSNs), hierarchical complexity (HC) and magnetisation transfer saturation imaging (MTsat). We will conduct: first, multivariable regressions and statistical association assessments to test how PTB-associated risk factors (PTB-RFs) relate to MSNs, HC and or MTsat; second, structural equation modelling to investigate neuroendocrine stress activation and immune dysregulation as mediators of PTB-RFs on features of EoP. PTB-RF selection will be informed by the variables that predict real-world educational outcomes, ascertained by linking the UK National Neonatal Research Database with the National Pupil Database.Ethics and disseminationA favourable ethical opinion has been given by the South East Scotland Research Ethics Committee 02 (23/SS/0067) and NHS Lothian Research and Development (2023/0150). Results will be reported to the Medical Research Council, in scientific media, via stakeholder partners and on a website in accessible language (https://www.ed.ac.uk/centre-reproductive-health/prencog).
Global contribution of suicide to maternal mortality: a systematic review protocol
Authors: Simmons Emma , Gong Jenny , Daskalopoulou Zoe , Quigley Maria A , Alderdice Fiona , Harrison Siân , Fellmeth Gracia 
Published: September 2024

IntroductionMaternal suicide is a significant contributor to maternal mortality with devastating consequences for women, families and society. Maternal mortality reporting systems differ across countries and there is no up-to-date overview of maternal suicide deaths globally. This systematic review aims to synthesise the evidence on maternal suicide. The primary objective is to determine the contribution of suicide towards maternal mortality globally and explore differences between geographical regions. The secondary objectives are to summarise the availability and quality of data globally and to describe how suicide deaths are classified across different countries.Methods and analysisThis protocol follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. Medline, Embase, PsycINFO, Global Health and CINAHL databases and the grey literature were searched with no date or language restrictions. Observational studies, national surveys and reports that present data on maternal deaths due to suicide occurring during pregnancy, intrapartum and in the postpartum period will be included. Screening, data extraction and quality assessment will be conducted independently by two reviewers. Results will be summarised narratively. If sufficient outcome data are available, random-effects meta-analyses will be conducted to determine global pooled estimates of suicide-related maternal mortality rates and the proportion of maternal deaths attributable to suicide.Ethics and disseminationEthical approval is not required for this systematic review. Results will be written up for publication in a peer-reviewed journal and findings will be shared at national and international conferences.PROSPERO registration numberCRD42023429072.
Quantum vortices in fermionic superfluids: from ultracold atoms to neutron stars.
Authors: Magierski Piotr , Barresi Andrea , Makowski Andrzej , Pcak Daniel , Wlazłowski Gabriel 
Published: September 2024

AbstractSuperfluid dilute neutron matter and ultracold gas, close to the unitary regime, exhibit several similarities. Therefore, to a certain extent, fermionic ultracold gases may serve as emulators of dilute neutron matter, which forms the inner crust of neutron stars and is not directly accessed experimentally. Quantum vortices are one of the most significant properties of neutron superfluid, essential for comprehending neutron stars’ dynamics. The structure and dynamics of quantum vortices as a function of pairing correlations’ strength are being investigated experimentally and theoretically in ultracold gases. Certain aspects of these studies are relevant to neutron stars. We provide an overview of the characteristics of quantum vortices in s-wave-type fermionic and electrically neutral superfluids. The main focus is on the dynamics of fermionic vortices and their intrinsic structure.
Opto-electro-thermal simulation of heat transfer in monocrystalline silicon solar cells
Authors: Tarifa Allyson , Lee Eon Soo , Ravindra Nuggehalli M. 
Published: September 2024

Abstract
In the area of photovoltaics, monocrystalline silicon solar cells are ubiquitously utilized in buildings, commercial, defense, residential, space, and transportation applications throughout the world. Their performance is impeded by the heating of the cells during their interaction with the incident solar radiation. The development of reliable computer simulations that effectively model the thermal response of monocrystalline silicon solar cells is critical for their design, fabrication, and utilization. This work employs a novel computer simulation to incorporate the optical, electrical, and thermal properties of silicon in the thermal analysis of silicon solar cells. After establishing the theoretical principles and the values of these properties, the results of the simulation are compared with other established studies. The analysis shows that the percentage difference in solar cell temperatures between simulation and literature is within a range of 0.354–0.487%. The proposed simulation shows that the visible range of wavelengths is the dominant source of heating in commercial monocrystalline silicon solar cells.
Keep It Moving: Physical Activity in the Prevention of Obesity-Driven Pancreatic Cancer
Authors: Sogunro Akin , Muzumdar Mandar D. 
Published: September 2024

Despite the already dire impact of pancreatic cancer, a growing subset of patients with obesity exhibits an amplified risk of disease and worse outcomes. Mouse models have revealed that obesity is distinctly pathogenic, accelerating pancreatic ductal adenocarcinoma (PDAC) progression and inducing increased desmoplasia and myeloid cell infiltration in the tumor microenvironment. However, whether and how obesity-countering interventions, such as exercise, reverse the protumorigenic effects of obesity is incompletely understood. In this issue of Cancer Research, Pita-Grisanti and colleagues investigate the impact of physical activity (PA) in disrupting obesity-driven PDAC. Employing a variety of sophisticated models, including autochthonous genetically engineered mice, orthotopic syngeneic allografts, high-fat diet–induced obesity, and PA interventions in mice and humans, the authors found that PA impedes PDAC development in obese mice but does not impact the growth of advanced tumors. These antitumor effects correlated with reduced inflammation and fibrosis in the tumor microenvironment, a decline in high-fat diet–induced circulating inflammatory cytokines, and an increase in the IL15 signaling axis in white adipose tissue. Although adipose-targeted IL15 therapy was effective in suppressing advanced tumor growth in lean mice, obese mice were resistant to its therapeutic benefits. Together, the findings argue that PA delays obesity-driven early PDAC progression, implicating the preferential benefit of exercise as a preventative strategy. They further identify changes in obesity-associated local and systemic cytokine production as a possible mechanism for the antitumor effects of PA and help define context-specific determinants of response for emerging IL15-based immunotherapies.See related article by Pita-Grisanti et al., p. 3058
Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer
Authors: Aguirre Andrew J. , Stanger Ben Z. , Maitra Anirban 
Published: September 2024

Abstract
KRAS is the most frequently altered oncogene in pancreatic ductal adenocarcinoma, in which the aberrantly activated RAS signaling pathway plays pleiotropic roles in tumor initiation and maintenance. Nearly four decades after the discovery of the RAS oncoprotein, a multitude of pharmacologic inhibitors are now available that directly target mutant KRAS. This In Focus commentary, published simultaneously with the 2024 AACR Special Conference on Pancreatic Cancer, summarizes the current state of this rapidly changing field, including preclinical data and emerging clinical trends with respect to therapeutic efficacy, mechanisms of resistance, and potential combinations to maximize clinical benefit from this promising class of therapies.
From Inception to Malignancy: the Co-evolution of Pancreatic Cancer and Its Immunosuppressive Microenvironment
Authors: Bednar Filip , Olsen Lee Y. , Pasca di Magliano Marina 
Published: September 2024

Abstract
Published in Cancer Research in 2007, Clark and colleagues first introduced the concept that the immune microenvironment evolves in lockstep with the progression of pancreatic cancer. Leveraging genetically engineered mouse models of the disease that were described a few years earlier, Clark and colleagues used a combination of approaches to describe the dynamics of immune evolution in precursor lesions all the way to overt malignancy. They discovered that immunosuppression is established at the earliest stages of carcinogenesis. Here, we discuss their findings, how they led to a wealth of functional work, and how they have been expanded upon since the advent of -omics technologies.
See related article by Clark and colleagues, Cancer Res 2007;67:9518–27
Pancreatic Cancer–Associated Fibroblasts: Where Do We Go from Here?
Authors: Carpenter Eileen S. , Vendramini-Costa Debora Barbosa , Hasselluhn Marie C. , Maitra Anirban , Olive Kenneth P. , Cukierman Edna , Pasca di Magliano Marina , Sherman Mara H. 
Published: September 2024

Abstract
Pancreatic ductal adenocarcinoma is a deadly disease and is projected to become the second leading cause of cancer-related death by 2030. A major hallmark is the exuberant host response comprising the tumor microenvironment, of which, cancer-associated fibroblasts (CAF) are a prevalent component. Despite the gains in understanding of their heterogeneity and functionality from CAF studies in recent years, there are many unanswered questions surrounding this diverse population of cells. Here, we summarize the views of several experts in the field, focusing on the current understanding of CAFs and challenges to address.
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression
Authors: Stacchiotti Silvia , Martini Silvia , Pasquali Sandro , Frezza Anna M. , Beretta Alessia , Percio Stefano , Lecchi Mara , Tortoreto Monica , Barisella Marta , Collini Paola , Dagrada Gian Paolo , Merlini Alessandra , Huang Paul H. , Jenks Andrew , Jones Robin L. , Tap William D. , Ingrosso Matilde , Morosi Carlo , Brich Silvia , Giani Claudia , Verderio Paolo , Casali Paolo G. , Leonard Hugh , Gronchi Alessandro , Zuco Valentina , Zaffaroni Nadia 
Published: September 2024

Abstract

Purpose:
Epithelioid hemangioendothelioma (EHE), an ultra-rare sarcoma, poses therapeutic challenges because of limited efficacy of conventional chemotherapy in advanced cases, necessitating exploration of new treatment avenues and identification of novel aggressive biomarkers. This study aimed at (i) utilizing a patient-derived xenograft model of EHE and its associated cell line to assess the efficacy of sirolimus and (ii) analyzing two distinct patient cohorts to pinpoint circulating biomarkers of EHE aggressiveness.

Experimental Design:
A patient-derived xenograft model and corresponding cell line were established from a patient with advanced EHE, demonstrating consistency with the original tumor in terms of histomorphology, WWTR1::CAMTA1 fusion presence, and genomic and transcriptomic profiles. Two independent patient series were employed to investigate the association between growth/differentiation factor 15 (GDF-15) serum levels and EHE aggressiveness.

Results:
ELISA analyses on EHE cell culture medium and blood from EHE-carrying mice revealed the release of GDF-15 by EHE cells. Sirolimus exhibited markedly higher antitumor activity compared with doxorubicin, concurrently reducing GDF-15 expression/release both in vivo and in vitro. This reduction was attributed to the drug-induced inhibition of phosphorylation/activation of 4E-BP1 and subsequent downregulation of the GDF-15 transcription factors ATF4 and ATF5. Blood sample analyses from two independent patient series showed a significant correlation between GDF-15 and EHE aggressiveness.

Conclusions:
This study identifies GDF-15 as a novel biomarker of EHE aggressiveness and underscores the superior efficacy of sirolimus compared with doxorubicin in our experimental models. The observed inhibition of GDF-15 release by sirolimus suggests its potential as a biomarker for monitoring the drug’s activity in patients.
Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial
Authors: Moura David S. , Lopez-Marti Jesus M. , Benesova Iva , de Andrea Carlos , di Lernia Davide , Lacerenza Serena , Mondaza-Hernandez Jose L. , Martin-Ruiz Marta , Ramirez-Calvo Marta , Grignani Giovanni , Martinez-Trufero Javier , Redondo Andres , Valverde Claudia , Stacchiotti Silvia , Lopez-Pousa Antonio , Lopez-Guerrero José A. , Gutierrez Antonio , Encinas-Tobajas Victor , Hindi Nadia , Sangiolo Dario , Lopez-Martin Jose A. , Strizova Zuzana Ozaniak , Martin-Broto Javier 
Published: September 2024

Purpose:
The IMMUNOSARC trial combined an antiangiogenic agent (sunitinib) with a PD1 inhibitor (nivolumab) in advanced sarcomas. Here, we present the first correlative studies of the soft-tissue sarcoma cohort enrolled in this trial.

Experimental Design:
Formalin-fixed paraffin-embedded and peripheral blood samples were collected at baseline and week 13. Formalin-fixed paraffin-embedded samples were used for transcriptomics and multiplex immunofluorescence, whereas peripheral blood samples were used for multiplexed immunoassays. Flow cytometry and Luminex assays were performed to validate translational findings in tumor-isolated cells and peripheral blood mononuclear cells derived from patients.

Results:
The density of intratumoral CD8+ T cells, measured by multiplexed immunophenotyping, was significantly increased after treatment. This augment was accompanied by the dynamic significant increase in the gene expressions of CD86, CHI3L1, CXCL10, CXCL9, LAG3, and VCAM1 and the decrease in the expression levels of NR4A1. In peripheral blood, 12 proteins were significantly modulated by treatment at week 13. A score integrating the dynamic expression of the 7 genes and the 12 soluble factors separated 2 groups with distinct progression-free survival (PFS): 4.1 months [95% confidence interval, 3.5–not reached (NR)] versus 17 months (95% confidence interval, 12.0–NR), P = 0.014. This molecular score was predictive of PFS when applied to the normalized data determined in the baseline samples.

Conclusions:
Treatment with sunitinib and nivolumab inflamed the sarcoma microenvironment, increasing CD8+ T-cell density and the expression of several genes/proteins with relevance in the response to PD1 inhibitors. A molecular signature identified two groups of patients with distinct PFS for the combination of antiangiogenics plus PD1 inhibitor therapy.
Desert–Oasis Convergence Line and Deep Convection Experiment (DECODE)
Authors: Meng Zhiyong , Meng Xuefeng , Wang Chenggang , Huang Yipeng , Zhang Shuhao , Liu Hongjun , Zhang Murong , Liu Yijing , Huang Hao , Su Lijuan , Cui Quxin , Lu Feng , Zhao Kun , Zhu Lei , Wang Li , Zhou Zhihua , Liu Linchun , Ma Xuefeng , Shan Jiutao , Xiao Yao , Zhu Daoru , Yang Zhengwei , Zheng Xucheng , Bo Fan , Bai Lanqiang , Yao Xiaojuan , Sun Yonggang , Lin Manyun , Zheng Zimeng , Zhou Liao , Wang Xuelei , Liu Ke , Chen Luyi , Yao Lebao , Guan Ming , Kong Weikang , Sun Shaoyang , Wang Jiaxin , Wu Yikai , Qin Yaqi , Jiang Xiaoying , Pan Xiang , Wang Mufei , Zhang Changan , Tuo Yanjun , Li Hanchao , Li Hui , Shi Lixia , Fang Xiaohong , Zhu Feng , Sun Xin , Yun Jingbo , Liu Shiyun , Wang Huiqing , Yang Yawen , Wen Jingyi , Wang Peiyu , Liu Lanbo , Ren Nan , Wu Xiufeng , Zhang Zhengyue , Pei Jianyu , Yang Zhi , Xia Cheng 
Published: September 2024

Abstract
The heterogeneous land surface spanning the Yellow River irrigated oasis and the adjacent Kubuqi and Ulan Buh Desert (Hetao area) in Inner Mongolia, China, has been noted to frequently generate planetary boundary layer convergence line (BLCL), providing an important source of low-level lifting for convection initiation (CI). As the first field experiment to collect comprehensive observations of vegetation-contrast-resulting thermal circulations that consistently generate BLCLs and lead to CI, the Desert–Oasis Convergence Line and Deep Convection Experiment (DECODE) was conducted from 5 July to 9 August 2022 in the Hetao area. Two oasis and four desert observation sites were set up in the region that exhibits the highest frequency of BLCL and CI occurrences, equipped with a suite of advanced instruments probing land–atmosphere interactions, planetary boundary layer processes, and evolution of BLCLs and their associated CI, including Doppler lidars, microwave radiometers, soil temperature and moisture sensors, eddy covariance systems, portable radiosondes, C-band polarimetric Doppler radar, aircraft, and Geostationary High-speed Imager onboard FY-4B satellite. DECODE captured 29 BLCLs (16 with CI), 66 gust fronts, 12 horizontal convective rolls, and one tornado. The observations unveiled full thermal circulations spanning the desert–oasis boundary characterized by a horizontal width of ∼25 km, a convergence height of ∼1 km above ground level (AGL), and divergence from 2 to ∼3.5 km AGL, with vertical wind speeds of up to 2 m s−1. Future publications stemming from DECODE will delve into a spectrum of scientific inquiries, including but not limited to land surface and boundary layer processes, BLCL dynamics, CI mechanisms, convective organization, predictability, and model evaluation.